Literature DB >> 15657574

Preventable reoperations for persistent and recurrent papillary thyroid carcinoma.

Maria A Kouvaraki1, Jeffrey E Lee, Suzanne E Shapiro, Steven I Sherman, Douglas B Evans.   

Abstract

BACKGROUND: Cervical recurrence occurs in up to 25% of patients with papillary thyroid carcinoma (PTC) due either to the aggressive biology of PTC or to inadequate treatment. This retrospective study was designed to determine the frequency of inadequate surgical or medical therapy as a cause of persistent or recurrent PTC.
METHODS: We identified all patients who underwent reoperation for persistent (within 6 months of initial or pre-referral operation) or recurrent (greater than 6 months after initial or pre-referral operation) PTC from 1992 to 2003. Medical records including initial preoperative imaging, operative, and histopathology reports were reviewed. The initial surgical procedure was considered incomplete if all gross neoplasm was not removed or if "node plucking" was performed, and a subsequent recurrence occurred in the same cervical compartment.
RESULTS: Seventy-two consecutive patients underwent reoperation for persistent (17) or recurrent (55) PTC. Of the 17 patients with persistent PTC, reoperation was judged to have been possibly preventable in 14 (82%) due to inadequate preoperative imaging or incomplete initial surgery. Of the 55 patients with recurrent PTC, reoperation was judged to have been possibly preventable due to incomplete initial surgery in 14 (25%). Based on the National Comprehensive Cancer Network guidelines, 33 (46%) of 72 patients with persistent or recurrent PTC received inadequate initial local treatment.
CONCLUSIONS: Reoperation in 28 (39%) of 72 patients with persistent or recurrent PTC was potentially preventable. Accurate preoperative staging and adherence to the suggested National Comprehensive Cancer Network treatment guidelines may minimize the need for cervical reoperation.

Entities:  

Mesh:

Year:  2004        PMID: 15657574     DOI: 10.1016/j.surg.2004.06.045

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  13 in total

Review 1.  Central lymph node dissection in differentiated thyroid cancer.

Authors:  Matthew L White; Paul G Gauger; Gerard M Doherty
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

2.  Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer.

Authors:  Don Yoo; Saad Ajmal; Shilpa Gowda; Jason Machan; Jack Monchik; Peter Mazzaglia
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  Predictors of Neck Reoperation and Mortality After Initial Total Thyroidectomy for Differentiated Thyroid Cancer.

Authors:  Thomas J Semrad; Theresa H M Keegan; Alison Semrad; Ann Brunson; D Gregory Farwell
Journal:  Thyroid       Date:  2018-07-26       Impact factor: 6.568

Review 5.  [Surgical assessment of complications after thyroid gland operations].

Authors:  H Dralle
Journal:  Chirurg       Date:  2015-01       Impact factor: 0.955

6.  Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system.

Authors:  N Chereau; T O Oyekunle; A Zambeli-Ljepović; H S Kazaure; S A Roman; F Menegaux; J A Sosa
Journal:  Br J Surg       Date:  2019-04-23       Impact factor: 6.939

Review 7.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

8.  [Surgery of thyroid carcinoma].

Authors:  H Dralle; K Lorenz; A Machens
Journal:  Chirurg       Date:  2009-11       Impact factor: 0.955

9.  BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

Authors:  Mingzhao Xing; Douglas Clark; Haixia Guan; Meiju Ji; Alan Dackiw; Kathryn A Carson; Matthew Kim; Anthony Tufaro; Paul Ladenson; Martha Zeiger; Ralph Tufano
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

10.  Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND.

Authors:  Ali S Alzahrani; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2013-01-21       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.